Views & Analysis Janssen: ‘Open dialogue’ needed with HTAs to improve access The world of life sciences is changing rapidly, and the traditional ways of assessing drugs may no longer be fit for purpose.
News J&J brings forward start of COVID-19 vaccine trial to next m... Johnson & Johnson has announced it has brought forward the start of its COVID-19 vaccine by around two months to mid-July.
Views & Analysis Deep Dive: Market Access - Breaking Barriers In this issue of Deep Dive we look at the changing landscape for pharma market access and start to assess the impact of the COVID-19 pandemic.
Views & Analysis Janssen’s Gaëtan Leblay on leading during the COVID-19 crisi... COVID-19 is putting unimaginable pressure on healthcare systems and the companies looking for solutions to end the pandemic.
News Nothing should stand in the way of coronavirus vaccine acces... Janssen’s chief scientific officer and worldwide chairman Paul Stoffels has said he hopes the company’s coronavirus vaccine candidate will be available by “early next year” to millions of people
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
